| The role of reactive oxygen species in acute myeloid leukaemia JR Sillar, ZP Germon, GN De Iuliis, MD Dun International journal of molecular sciences 20 (23), 6003, 2019 | 113 | 2019 |
| Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma RJ Duchatel, A Mannan, AS Woldu, T Hawtrey, PA Hindley, AM Douglas, ... Neuro-oncology advances 3 (1), vdab169, 2021 | 35 | 2021 |
| ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma ER Jackson, RJ Duchatel, DE Staudt, ML Persson, A Mannan, S Yadavilli, ... Cancer research 83 (14), 2421-2437, 2023 | 22 | 2023 |
| Shwachman–Bodian–Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia MD Dun, A Mannan, CJ Rigby, S Butler, HD Toop, D Beck, P Connerty, ... Leukemia 34 (12), 3393-3397, 2020 | 17 | 2020 |
| Reactive oxygen species in acute lymphoblastic leukaemia: reducing radicals to refine responses A Mannan, ZP Germon, J Chamberlain, JR Sillar, B Nixon, MD Dun Antioxidants 10 (10), 1616, 2021 | 14 | 2021 |
| B-cell lymphoma 6 (BCL6): from master regulator of humoral immunity to oncogenic driver in pediatric cancers T McLachlan, WC Matthews, ER Jackson, DE Staudt, AM Douglas, ... Molecular Cancer Research 20 (12), 1711-1723, 2022 | 11 | 2022 |
| Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies ZP Germon, JR Sillar, A Mannan, RJ Duchatel, D Staudt, HC Murray, ... Science Signaling 16 (778), eabp9586, 2023 | 7 | 2023 |
| Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection DE Staudt, HC Murray, DA Skerrett-Byrne, ND Smith, MFB Jamaluddin, ... Clinical proteomics 19 (1), 48, 2022 | 3 | 2022 |
| PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma RJ Duchatel, ER Jackson, SG Parackal, D Kiltschewskij, IJ Findlay, ... The Journal of clinical investigation 134 (6), 2024 | 2 | 2024 |
| Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia S Humphries, DR Bond, ZP Germon, S Keely, AK Enjeti, MD Dun, HJ Lee Clinical epigenetics 15 (1), 150, 2023 | 2 | 2023 |
| Blockade of redox second messengers inhibits JAK/STAT and MEK/ERK signaling sensitizing FLT3-mutant acute myeloid leukemia to targeted therapies ZP Germon, JR Sillar, A Mannan, RJ Duchatel, D Staudt, HC Murray, ... bioRxiv, 2022.03. 09.483687, 2022 | 1 | 2022 |
| EXTH-36. COMBINING ONC201 AND PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA (DMG); THE PRECLINICAL RESULTS UNDERPINNING THE INTERNATIONAL PHASE II CLINICAL TRIAL … E Jackson, R Duchatel, D Staudt, M Persson, A Mannan, S Yadavilli, ... Neuro-Oncology 25 (Supplement_5), v232-v232, 2023 | | 2023 |
| EXTH-31. EXPLOITING THE GENETIC DEPENDENCY ON PI3K/MTOR SIGNALING FOR THE TREATMENT OF H3-ALTERED DIFFUSE MIDLINE GLIOMA R Duchatel, E Jackson, S Parackal, C Sun, P Daniel, A Mannan, I Findlay, ... Neuro-Oncology 25 (Supplement_5), v230-v231, 2023 | | 2023 |
| EXTH-12. PRECLINICAL AND CASE STUDY EXAMINATION OF THE COMBINATION OF THE CLPP AGONIST ONC201 WITH THE PI3K/AKT INHIBITOR PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA E Jackson, R Duchatel, M Persson, A Mannan, S Yadavilli, S Parackal, ... Neuro-Oncology 24 (Supplement_7), vii211-vii211, 2022 | | 2022 |
| DIPG-07. Preclinical and case study results underpinning the phase II clinical trial testing the combination of ONC201 and paxalisib for the treatment of patients with diffuse … MD Dun, ER Jackson, RJ Duchatel, ML Persson, A Mannan, S Yadavilli, ... Neuro-Oncology 24 (Supplement_1), i18-i19, 2022 | | 2022 |
| High-Throughput Global Phosphoproteomic Profiling Using Phospho Heavy-Labeled-Spiketide FAIMS Stepped-CV DDA (pHASED) DE Staudt, HC Murray, DA Skerrett-Byrne, ND Smith, MF Jamaluddin, ... bioRxiv, 2022.04. 22.489124, 2022 | | 2022 |
| Dun. MD Reactive Oxygen Species in Acute Lymphoblastic Leukaemia: Reducing Radicals to Refine Response. Antioxidants 2021, 10, 1616 A Mannan, ZP Germon, J Chamberlain, J Sillar, B Nixon s Note: MDPI stays neu-tral with regard to jurisdictional claims in …, 2021 | | 2021 |
| Reactive oxygen species in FLT3-ITD+ acute myeloid leukemia contributes to oncogenic signaling and is a novel treatment target ZP Germon, JR Sillar, A Mannan, R Duchatel, HC Murray, A Douglas, ... Asia Pacific Journal of Clinical Oncology 16 (Suppl. 6), 25-26, 2020 | | 2020 |
| The use of low-THC cannabis and non-THC cannabinoids in the complementary treatment of acute myeloid leukemia (AML) F Afrin, M Chi, A Woldu, R Duchatel, AM Douglas, Z Germon, DS Barreto, ... ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 16, 30-31, 2020 | | 2020 |
| Targeting oxidative stress in high-risk pediatric acute lymphoblastic leukemia A Mannan, ZP Germon, J Sillar, RJ Duchatel, A Douglas, K McCarthy, ... ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 16, 30-30, 2020 | | 2020 |
